Cargando…
Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10‐day decitabine regimen
Decitabine has been explored as a reduced‐intensity therapy for older or unfit patients with acute myeloid leukemia (AML). To better understand the risk of infections during decitabine treatment, we retrospectively examined the culture results from each infection‐related serious adverse event that o...
Autores principales: | Ali, Alaa M., Weisel, Daniel, Gao, Feng, Uy, Geoffrey L., Cashen, Amanda F., Jacoby, Meagan A., Wartman, Lukas D., Ghobadi, Armin, Pusic, Iskra, Romee, Rizwan, Fehniger, Todd A., Stockerl‐Goldstein, Keith E., Vij, Ravi, Oh, Stephen T., Abboud, Camille N., Schroeder, Mark A., Westervelt, Peter, DiPersio, John F., Welch, John S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5727246/ https://www.ncbi.nlm.nih.gov/pubmed/29058375 http://dx.doi.org/10.1002/cam4.1231 |
Ejemplares similares
-
Decitabine salvage for TP53-mutated, relapsed/refractory acute myeloid leukemia after cytotoxic induction therapy
por: Ferraro, Francesca, et al.
Publicado: (2022) -
Impact of a 40-Gene Targeted Panel Test on Physician Decision Making for Patients With Acute Myeloid Leukemia
por: Barnell, Erica K., et al.
Publicado: (2021) -
Epidemiology of infections following haploidentical peripheral blood hematopoietic cell transplantation
por: Slade, Michael, et al.
Publicado: (2016) -
A phase 1/2 study of chemosensitization with plerixafor plus G-CSF in relapsed or refractory acute myeloid leukemia
por: Uy, G L, et al.
Publicado: (2017) -
Decitabine in the treatment of myelodysplastic syndromes
por: Saba, Hussain I
Publicado: (2007)